Streetwise Reports' Article Archives — April 2018 back to current month (10)
Risk Versus Reward: The Value of Cell Therapy for Patients and Investors (04/25/2018)
The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late-stage development. In the first of a two-part series examining the disruptive technology, Maxim Group analyst Jason McCarthy exposes the upsides and downsides of the space, and the companies at its forefront.
Analyst Sees Tenbagger in Biotech Firm with 'Favorable Updates' (04/24/2018)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., relayed the most recent news concerning this firm's drug candidate.
Biotech Round-Up: M&As, Financings and Immuno-Oncology (04/18/2018)
John McCamant, editor of Medical Technology Stock Letter, reviews biotech M&A and financings, and discusses one company that is expanding its immuno-oncology pipeline.
Major Cannabis Player Sees Florida Sales Surge Over 250% and Will Acquire 75% Ownership in Massachusetts Deal (04/17/2018)
A medicinal cannabis company has seen its Florida sales increase 253%, and the company just gained 75% control over a Massachusetts-based dispensary operation, expanding its influence in the medicinal marijuana industry.
Biotech Gets Cashed Up Ahead of Pivotal Phase 3 Readouts (04/17/2018)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., discussed the capital raise and upcoming clinical trial data.
Biotech with Deep Pipeline, 'Abundant' Upcoming Catalysts Named Top Pick (04/11/2018)
Douglas Loe, an analyst with Echelon Wealth Partners, made the case for why this biopharmaceutical company merits this status.
Biotech Announces Positive Topline Data in Tourette Syndrome (04/11/2018)
Francois Brisebois, a Laidlaw & Co. analyst, reviewed the recently released study results and upcoming catalysts.
RNAi Therapeutics Developer Reports Positive Amyloidosis Data (04/04/2018)
Michael King, an analyst with JMP Securities, reported the new results that this biotech presented in March.
CMS Unexpectedly Issues Product Billing Code to Biotech (04/04/2018)
Francois Brisebois, an analyst with Laidlaw & Co., shared and weighed in on the latest news regarding this biopharmaceutical firm.
Biotech Delivers 'Excellent' Phase 2 Data (04/03/2018)
John McCamant, editor of Medical Technology Stock Letter, discusses a biotech with data that he views as positive from a Phase 2 LDL cholesterol lowering trial.
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec